SNT-101 / Sonata Therap - LARVOL DELTA

Sonata Therapeutics Presents Data Supporting its Network Medicines Approach at SITC 2023 (Businesswire) - "Sonata Therapeutics, Inc...will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The posters highlight Sonata’s proprietary Intrinsic Antigen Release Technology (iART) and two of the company’s oncology programs, all of which demonstrated in vivo efficacy in a variety of tumor models...Key takeaways...Delivered intratumorally, SNT-3010912 induced a state-of-the-art form of enhanced immunogenic antigen release...Mice treated with SNT-20109 showed significant tumor growth inhibition, and nine of the ten subjects showed complete regression, indicating it could drive a unique immunological cascade with broad potential for future cancer treatment investigations....SNT-101 potently reduced viability, and induced cell death and lipid peroxidation in both cell lines, resulting in significant target exposure and tumor growth inhibition."

Preclinical • Oncology • Solid Tumor

Exploring novel ferroptosis inducer as a promising strategy for sarcoma treatment (SITC 2023) - "Results The compound 101 potently reduced viability, induced cell death and lipid peroxidation in both cell lines...We found that our compound has an improved efficacy compared with pazopanib...Our findings highlight the potential of inducing ferroptosis as a promising strategy in sarcomas. Further investigations are warranted to validate our ferroptosis inducers as a therapeutic approach in sarcoma patients."

Fibrosarcoma • Oncology • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • GPX4 • HMGB1